Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and Meta-analysis

Author(s): Brian Mendel*, Christianto, Moira Setiawan, Sisca Natalia Siagian and Radityo Prakoso

Volume 18, Issue 5, 2022

Published on: 27 May, 2022

Article ID: e040422203048 Pages: 16

DOI: 10.2174/1573403X18666220404101610

Price: $65

Abstract

Background: The Fontan procedure is currently the mainstay therapy for single functional ventricles. However, with prolonged follow-up duration, various complications have been observed that seriously influence the quality of life of patients.

Objectives: The aim of this meta-analysis is to compare the effectiveness of pharmacologic agents in improving exercise capacity in patients with Fontan circulation.

Methods: This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement and has been registered in the International Prospective Register for Systematic Reviews database with registration no. 282352. Quality assessments of the included studies were assessed using the Strengthening Reporting of Observational Studies in Epidemiology (STROBE) statement.

Results: Twelve studies met the predetermined inclusion criteria and were included in this metaanalysis. This meta-analysis found that treatment with bosentan significantly improved New York Heart Association Functional Class (NYHA FC) in Fontan patients (standard mean difference - 0.59, 95% CI -0.94 – -0.25; P=0.0008; I2 = 1%). However, the use of bosentan (P=0.66) and sildenafil (P=0.13) did not show a significant improvement in the maximum rate of oxygen consumption (VO2 max).

Conclusion: This meta-analysis shows that people with Fontan circulation may benefit from using bosentan as it decreases postexercise heart rate and improves NYHA FC and 6-minute walking test results. Therefore, indirectly improving exercise capacity. Nonetheless, considerable work is required to strengthen our knowledge in improving the exercise capacity of Fontan patients.

Keywords: Bosentan, exercise capacity, Fontan, sildenafil, vasodilator, patients.

Graphical Abstract

[1]
de Leval MR. The Fontan circulation: A challenge to William Harvey. Nat Clin Pract Cardiovasc Med 2005; 2(4): 202-8.
[http://dx.doi.org/10.1038/ncpcardio0157] [PMID: 16265484]
[2]
Gewillig M. The Fontan circulation. Heart 2005; 91(6): 839-46.
[http://dx.doi.org/10.1136/hrt.2004.051789] [PMID: 15894794]
[3]
Hosein RBM, Clarke AJB, McGuirk SP, et al. Factors influencing early and late outcome following the Fontan procedure in the current era. The ‘Two Commandments’. Eur J Cardiothorac Surg 2007; 31(3): 344-52.
[http://dx.doi.org/10.1016/j.ejcts.2006.11.043] [PMID: 17236782]
[4]
Ono M, Boethig D, Goerler H, Lange M, Westhoff-Bleck M, Breymann T. Clinical outcome of patients 20 years after Fontan operation--effect of fenestration on late morbidity. Eur J Cardiothorac Surg 2006; 30(6): 923-9.
[http://dx.doi.org/10.1016/j.ejcts.2006.08.025] [PMID: 17074498]
[5]
Idorn L, Olsen M, Jensen AS, et al. Univentricular hearts in Denmark 1977 to 2009: Incidence and survival. Int J Cardiol 2013; 167(4): 1311-6.
[http://dx.doi.org/10.1016/j.ijcard.2012.03.182] [PMID: 22521378]
[6]
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6(7)e1000097
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[7]
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg 2014; 12(12): 1495-9.
[http://dx.doi.org/10.1016/j.ijsu.2014.07.013] [PMID: 25046131]
[8]
Giordano R, Palma G, Poli V, et al. First experience with sildenafil after Fontan operation: Short-term outcomes. J Cardiovasc Med (Hagerstown) 2015; 16(8): 552-5.
[http://dx.doi.org/10.2459/JCM.0b013e328361390a] [PMID: 23588032]
[9]
Bowater SE, Weaver RA, Thorne SA, Clift PF. The safety and effects of bosentan in patients with a Fontan circulation. Congenit Heart Dis 2012; 7(3): 243-9.
[http://dx.doi.org/10.1111/j.1747-0803.2012.00635.x] [PMID: 22348734]
[10]
Derk G, Houser L, Miner P, et al. Efficacy of endothelin blockade in adults with Fontan physiology. Congenit Heart Dis 2015; 10(1): E11-6.
[http://dx.doi.org/10.1111/chd.12189] [PMID: 24890846]
[11]
Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: The TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measur-ing peak oxygen consumption) study. Circulation 2014; 130(23): 2021-30.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.008441] [PMID: 25446057]
[12]
Schuuring MJ, Vis JC, van Dijk APJ, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: A randomized controlled trial. Eur J Heart Fail 2013; 15(6): 690-8.
[http://dx.doi.org/10.1093/eurjhf/hft017] [PMID: 23361871]
[13]
Agnoletti G, Gala S, Ferroni F, et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in pa-tients with Fontan circulation. J Thorac Cardiovasc Surg 2017; 153(6): 1468-75.
[http://dx.doi.org/10.1016/j.jtcvs.2017.01.051] [PMID: 28283234]
[14]
Shang X ke, Lu R, Zhang X. Efficacy of Bosentan in patients after Fontan procedures: A double-blind, randomized controlled trial. J Huazhong Univ Sci Technol -. Med Sci 2016; 36: 534-40.
[15]
Hager A, Weber R, Müller J, Hess J. Predictors of sildenafil effects on exercise capacity in adolescents and adults with Fontan circulation. Clin Res Cardiol 2014; 103(8): 641-6.
[http://dx.doi.org/10.1007/s00392-014-0694-2] [PMID: 24639042]
[16]
Van De Bruaene A, La Gerche A, Claessen G, et al. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging 2014; 7(2): 265-73.
[http://dx.doi.org/10.1161/CIRCIMAGING.113.001243] [PMID: 24478333]
[17]
Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29(13): 1681-7.
[http://dx.doi.org/10.1093/eurheartj/ehn215] [PMID: 18534975]
[18]
Mori H, Park IS, Yamagishi H, et al. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol 2016; 221: 122-7.
[http://dx.doi.org/10.1016/j.ijcard.2016.06.322] [PMID: 27400308]
[19]
Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: A randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011; 123(11): 1185-93.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.981746] [PMID: 21382896]
[20]
Sabri MR, Zolfi-Gol A, Ahmadi A, Haghjooy-Javanmard S. Effect of tadalafil on myocardial and endothelial function and exercise per-formance after modified fontan operation. Pediatr Cardiol 2016; 37(1): 55-61.
[http://dx.doi.org/10.1007/s00246-015-1238-x] [PMID: 26215768]
[21]
Rhodes J, Ubeda-Tikkanen A, Clair M, et al. Effect of inhaled iloprost on the exercise function of Fontan patients: A demonstration of concept. Int J Cardiol 2013; 168(3): 2435-40.
[http://dx.doi.org/10.1016/j.ijcard.2013.03.014] [PMID: 23545150]
[22]
Latus H, Gerstner B, Kerst G, et al. Effect of inhaled nitric oxide on blood flow dynamics in patients after the fontan procedure using cardiovascular magnetic resonance flow measurements. Pediatr Cardiol 2016; 37(3): 504-11.
[http://dx.doi.org/10.1007/s00246-015-1307-1] [PMID: 26547436]
[23]
Cedars AM, Saef J, Peterson LR, et al. Effect of ambrisentan on exercise capacity in adult patients after the fontan procedure. Am J Cardiol 2016; 117(9): 1524-32.
[http://dx.doi.org/10.1016/j.amjcard.2016.02.024] [PMID: 27063478]
[24]
Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young 2009; 19(4): 331-9.
[http://dx.doi.org/10.1017/S1047951109990023] [PMID: 19519964]
[25]
Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006; 2(4): 411-22.
[http://dx.doi.org/10.2147/vhrm.2006.2.4.411] [PMID: 17323595]
[26]
Vizza CD, Sastry BKS, Safdar Z, et al. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hyper-tension: A randomized, double-blind study with open-label extension. BMC Pulm Med 2017; 17(1): 44.
[http://dx.doi.org/10.1186/s12890-017-0374-x] [PMID: 28228114]
[27]
Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20): 2148-57.
[http://dx.doi.org/10.1056/NEJMoa050010] [PMID: 16291984]
[28]
Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: An evidence-based review. Core Evid 2015; 10: 99-109.
[PMID: 26587013]
[29]
Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61(3): 280-8.
[http://dx.doi.org/10.1111/j.1365-2125.2005.02553.x] [PMID: 16487221]
[30]
Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43(15): 1089-115.
[http://dx.doi.org/10.2165/00003088-200443150-00003] [PMID: 15568889]
[31]
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12): 896-903.
[http://dx.doi.org/10.1056/NEJMoa012212] [PMID: 11907289]
[32]
Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007; 3(6): 887-900.
[PMID: 18200808]
[33]
Rivera-Lebron BN, Risbano MG. Ambrisentan: A review of its use in pulmonary arterial hypertension. Ther Adv Respir Dis 2017; 11(6): 233-44.
[http://dx.doi.org/10.1177/1753465817696040] [PMID: 28425346]
[34]
Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117(23): 3010-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.742510] [PMID: 18506008]
[35]
Ewert R, Schäper C, Halank M, Gläser S, Opitz CF. Inhalative iloprost - pharmacology and clinical application. Expert Opin Pharmacother 2009; 10(13): 2195-207.
[http://dx.doi.org/10.1517/14656560903164228] [PMID: 19663611]
[36]
Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev 2009; 18: 29-34.
[http://dx.doi.org/10.1183/09059180.00011111]
[37]
Chester AH, Yacoub MH, Moncada S. Nitric oxide and pulmonary arterial hypertension. Glob Cardiol Sci Pract 2017; 2017(2): 14.
[http://dx.doi.org/10.21542/gcsp.2017.14] [PMID: 29644226]
[38]
Schroeder RA, Kuo PC. Nitric oxide: Physiology and pharmacology. Anesth Analg 1995; 81(5): 1052-9.
[39]
Sim J-Y. Nitric oxide and pulmonary hypertension. Korean J Anesthesiol 2010; 58(1): 4-14.
[http://dx.doi.org/10.4097/kjae.2010.58.1.4] [PMID: 20498805]
[40]
Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmo-nary vasoconstriction. Circulation 1991; 83(6): 2038-47.
[http://dx.doi.org/10.1161/01.CIR.83.6.2038] [PMID: 2040056]
[41]
Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. J Soc Toxicol 2001; 59: 5-16.
[42]
Fumito I. RJ D, ZW M. Inhaled nitric oxide. Circulation 2004; 109: 3106-11.
[43]
Crapo RO, Casaburi R, Coates AL, et al. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1): 111-7.
[http://dx.doi.org/10.1164/ajrccm.166.1.at1102] [PMID: 12091180]
[44]
Claessen G, La Gerche A, Van De Bruaene A, et al. Heart rate reserve in fontan patients: Chronotropic incompetence or hemodynamic limitation? J Am Heart Assoc 2019; 8(9)e012008
[http://dx.doi.org/10.1161/JAHA.119.012008] [PMID: 31041880]
[45]
Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan pro-cedure. Circulation 1997; 96(5): 1507-12.
[http://dx.doi.org/10.1161/01.CIR.96.5.1507] [PMID: 9315539]
[46]
François K, Bové T, De Groote K, et al. Pleural effusions, water balance mediators and the influence of lisinopril after completion Fontan procedures. Eur J Cardiothorac Surg 2009; 36(1): 57-62.
[http://dx.doi.org/10.1016/j.ejcts.2009.02.059] [PMID: 19369086]

Rights & Permissions Print Cite
Article Metrics
29
2
© 2024 Bentham Science Publishers | Privacy Policy